Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659136 · ClinicalTrials.gov registry record · Phase 2
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT03659136 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 103 participants.
The verdict
NCT03659136, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Interventions
- DRUG Placebo
- DRUG Exemestane
- DRUG Everolimus
- DRUG Xentuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03659136
The ClinicalTrials.gov registry entry for NCT03659136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03659136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03659136 about?
NCT03659136 is a clinical study titled "The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread". The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
What is the current status of trial NCT03659136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2018-11-28. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT03659136?
The interventions under investigation include: Placebo (DRUG), Exemestane (DRUG), Everolimus (DRUG), Xentuzumab (DRUG).
Who is sponsoring clinical trial NCT03659136?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.